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Background: The incidence and prevalence of multiple endocrine neoplasia 2A (MEN2A) have 
only been reported once in a nationwide setting. However, it is unclear whether the figures are 
representative of other populations, as the major component of the syndrome, hereditary med-
ullary thyroid carcinoma (MTC), has been reported as rare in the same country. We conducted 
a nationwide retrospective cohort study of MEN2A in Denmark from 1901 to 2014, aiming to 
describe the incidence and prevalence.
Methods: This study included 250 unique MEN2A patients born or resident in Denmark before 
December 31, 2014. Patients were identified through the Danish REarranged during Transfection 
(RET) cohort, linkage of MEN2A pedigrees, the Danish MTC cohort, a nationwide collaboration 
of MEN2 centers, cross-checking of other relevant cohorts, and a systematic literature search.
Results: The incidence from 1971 to 2000 was 28 (95% CI: 21–37) per million live births 
per year. Incidence for the specific mutations or for the overall MEN2A group did not change 
significantly from 1901 to 2014 (P>0.05). Point prevalence at January 1, 2015, was 24 per 
million (95% CI: 20–28).
Conclusion: The incidence and prevalence of MEN2A in Denmark seem higher than those 
reported in other countries. This is likely explained by the Danish C611Y founder effect. Also, 
our data indicate no significant change in MEN2A incidence during the last century.
Keywords: multiple endocrine neoplasia 2A, incidence, prevalence, Denmark
Introduction
Multiple endocrine neoplasia 2 (MEN2) is an autosomal-dominant inherited cancer 
syndrome subdivided into MEN2A and MEN2B. MEN2A associates medullary thy-
roid carcinoma (MTC), pheochromocytoma, hyperparathyroidism, cutaneous lichen 
amyloidosis, and Hirschsprung’s disease. MEN2B associates MTC, pheochromocy-
toma, and ganglioneuromatosis of the aerodigestive tract, and facial, ophthalmologic, 
and skeletal abnormalities. Both syndromes are caused by germline mutations of the 
REarranged during Transfection (RET) proto-oncogene.1
The incidence and prevalence of MEN2B have recently been well described.2–4 
Meanwhile, the epidemiology of MEN2A remains poorly defined. Only two stud-
ies, a German and a Norwegian, have calculated the incidence and prevalence of 
MEN2A.2,5 The German study was based on data from two major referral centers and 
estimated that at least half of all RET carriers born between 1991 and 2000 had been 
captured.2 The Norwegian study was population-based and covered all RET mutation 
carriers born in Norway between 1965 and 2015.5 However, it is unclear whether the 
Norwegian figures are representative of other populations, as the major component 
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of the syndrome, hereditary MTC, has been reported as rare 
in another Norwegian study.6
Consequently, we conducted a nationwide study of 
MEN2A in Denmark from 1901 to 2014, aiming to describe 
the incidence and prevalence.
Methods
Study design and setting
This retrospective cohort study included 250 unique MEN2A 
patients born or resident in Denmark before December 31, 
2014.
Data sources
1. The Danish RET cohort formed the basis for identify-
ing MEN2A patients. This nationwide cohort contains 
all patients (n=1,583) RET tested in Denmark between 
September 1994 and December 2014.7
2. Pedigree linkage within the RET cohort was used to iden-
tify MEN2A patients, who had not been RET tested. Thus, 
we sought to find linkage between the MEN2A patients 
from the RET cohort carrying identical mutations. For 
this purpose, we excluded MEN2A patients with famil-
ial origin outside Denmark, molecular proven de novo 
mutations, and unique mutations within the RET cohort 
(Table 1). Pedigrees were constructed with a minimum of 
four generations by dint of the Civil Registration System 
(www.cpr.dk) and the Danish National Archives (www.
sa.dk/en/) before comparing with one another. Where 
linkage was found, this was validated by haplotype.8
3. The Danish MTC cohort was searched for MEN2A 
patients.9 This cohort comprises 476 patients diagnosed 
with histological (n=474) or cytological (n=2) MTC in 
Denmark between January 1960 and December 2014 
and was constructed through three nationwide registries: 
Table 1 MEN2A families with RET germline mutationsa detected in Denmark and includedb in this study
Family no. Exon Nucleotide change Sequence change RET+c/RET- Reference
1d 10 c.1833C>G C611W 6/11
2 10 c.1832G>A C611Y 2/0 24
3 10 c.1832G>A C611Y 1/0
4 10 c.1832G>A C611Y 8/3
5 10 c.1832G>A C611Y 15/13
6 10 c.1832G>A C611Y 2/0 21
7 10 c.1832G>A C611Y 9/7 21
8 10 c.1832G>A C611Y 2/6
9 10 c.1832G>A C611Y 26/27
10 10 c.1832G>A C611Y 30/30 22
11 10 c.1832G>A C611Y 1/3
12 10 c.1832G>A C611Y 5/18 20
13 10 c.1832G>A C611Y 7/8
14 10 c.1853G>T C618F 1/1
15 10 c.1853G>T C618F 2/1 21
16 10 c.1853G>A C618Y 5/9
17 10 c.1853G>A C618Y 3/3 21
18 10 c.1858T>C C620R 6/5 23
19 10 c.1858T>C C620R 3/3 21
20e 10 c.1858T>C C620R 1/3 21
21d 11 c.1891G>T D631Y 1/0
22 11 c.1900T>C C634R 2/0
23 11 c.1900T>C C634R 1/2 21
24 11 c.1900T>C C634R 3/11 22
25 11 c.1900T>C C634R 1/5 21
26d,f 11 c.1901G>A C634Y 2/0
27d,f 11+13 c.1901G>A+ c.2372A>T C634Y+Y791F 1/2
28d,f 13 c.2370G>T L790F 5/2
29d 14 c.2410G>A V804M 2/1
37 11 c.1900T>C C634R 1/0
Notes: Modified from Table 2 of Mathiesen et al.7 Family no. 1–29 and 37 were identified from the Danish RET cohort 1994–2014 and the Danish MTC cohort 1960–2014, 
respectively.7,9 aSequence changes classified as pathogenic in the ARUP MEN2 database May 1, 2018.15 bFamily no. 30–36 were excluded as they had MEN2B; cRET+ includes 
index cases. dFamilies with unique mutations in Denmark. eFamily in which both parents of the index case were tested mutation negative. fFamilies with origin outside 
Denmark.
Abbreviations: MEN2, multiple endocrine neoplasia 2; MTC, medullary thyroid carcinoma; RET, REarranged during Transfection.
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the Danish Thyroid Cancer Database, the Danish Cancer 
Registry, and the Danish Pathology Register.10–12
4. A nationwide collaboration of all Danish MEN2 treat-
ment centers (Copenhagen University Hospital, Aarhus 
University Hospital, Odense University Hospital, and 
Aalborg University Hospital) was established for MEN2A 
identification. Upon inquiry, each center contributed with 
all MEN2A patients locally registered until December 31, 
2014.
Based on the abovementioned sources, we drew pedigrees 
from the MEN2A patients and detected the first-degree rela-
tives, who had not been RET tested.
5. A cross-check between the first-degree relatives of the 
already identified MEN2A patients and the Danish 
MTC cohort and other relevant cohorts was performed. 
The other relevant cohorts were identified through two 
nationwide registries: the Danish Pathology Register and 
the Danish National Patient Registry.12,13 Cohorts from 
the Danish Pathology Register included patients histo-
logically or cytologically diagnosed between September 
1968 and December 2014 and comprise a pheochromocy-
toma cohort, hyperparathyroidism cohort, Hirschsprung 
cohort, and MEN2A cohort. Cohorts from the  Danish 
National Patient Registry included patients coded 
between 1976 and 2014 and comprise a pheochromocy-
toma cohort, hyperparathyroidism cohort, Hirschsprung 
cohort, multiple endocrine neoplasia cohort, and lichen 
amyloidosis cohort. All cohorts have been described in 
detail elsewhere.9 Cohorts with identical names were 
combined before the cross-check, yielding pheochromo-
cytoma, hyperparathyroidism, Hirschsprung, and multiple 
endocrine neoplasia cohort of 1,298, 15,802, 1,516, and 
426 unique patients, respectively. The lichen amyloidosis 
cohort included six patients.
6. A cross-check of the MTC cohort, pheochromocytoma 
cohort, hyperparathyroidism cohort, Hirschsprung 
cohort, and lichen amyloidosis cohort against one another 
was conducted by use of the unique personal identifica-
tion number issued to each individual in Denmark upon 
birth or immigration.14 The multiple endocrine neoplasia 
cohort was cross-checked against all other cohorts except 
the hyperparathyroidism cohort, as this would result in 
multiple false-positive cases due to the association of 
multiple endocrine neoplasia 1 and hyperparathyroidism.
7. A systematic literature search was performed on  December 
7, 2017, in the following databases: Cochrane, Embase, 
PubMed, Scopus, and Web of Science. The search term 
used was “medullary thyroid carcinoma Denmark OR 
medullary thyroid carcinoma Danish OR multiple endo-
crine neoplasia 2 Denmark OR multiple endocrine neo-
plasia 2 Danish.” No filters were used. MEN2A patients 
were traced by data on the patient (sex, age, MEN2A 
features, RET mutation) and pedigree level provided by 
the respective citations. These data were compared with 
the data gathered throughout the previous six steps.
MEN2A criteria
If genetic tested, a MEN2 patient was defined as 1) an indi-
vidual with a pathogenic RET germline sequence change 
and a MEN2A phenotype in the ARUP MEN2 database on 
May 1, 2018.15
If not genetic tested, a MEN2A patient was defined 
as 2) an individual with a MEN2A feature (histologically 
verified MTC/pheochromocytoma/Hirschsprung’s disease 
or clinically diagnosed cutaneous lichen) and relatedness 
to an individual fulfilling 1), or 3) an individual without a 
proven MEN2A feature, but providing linkage between two 
individuals fulfilling 1), or 4) an individual without a proven 
MEN2A feature, but providing linkage between a patient 
with a MEN2A feature and an individual fulfilling 1), or 5) 
an individual with >1 MEN2A feature.
Study participants
Figure 1 shows an overview of inclusion of MEN2A patients 
according to data sources.
1. The Danish RET cohort initially contained 36 MEN2 
families. For the purpose of this study, all MEN2B fami-
lies (n=6), three of which have been described elsewhere, 
were excluded.16–19 This left 30 MEN2A families with 
155 RET mutation carriers. Several of these have been 
reported previously.20–24 One family with three carriers 
has subsequently been excluded from the cohort, as the 
pathogenicity of the RET I852M variant has been ques-
tioned and reclassified in the ARUP MEN2 database.15,25 
In a C634R family, one patient initially had the RET test 
interpreted as negative. A recent revaluation, however, 
identified the mutation. This resulted in 153 MEN2A 
patients from 29 families fulfilling criterion 1) (Table 1).
2. Pedigree linkage between the MEN2A patients from 
the RET cohort carrying identical mutations identified 
54 MEN2A patients. All 54 patients were new. Six and 
forty-eight fulfilled criteria 2) and 3), respectively. This 
reduced the number of C611Y families from twelve to 
three and the number of C618Y families from two to 
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Figure 1 Flow chart showing identification of MEN2A patients. Dotted boxes indicate methods used and additional MEN2A patients for inclusion.
Notes: aCopenhagen University Hospital, Aarhus University Hospital, Odense University Hospital, and Aalborg University Hospital. bDanish MTC cohort, pheochromocytoma 
cohort, hyperparathyroidism cohort, Hirschsprung cohort, multiple endocrine neoplasia cohort, and lichen amyloidosis cohort.
Abbreviations: MEN2A, multiple endocrine neoplasia 2A; RET, Rearranged during Transfection.
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one. Thus, after this step we had identified 207 MEN2A 
patients from 19 families.
3. The Danish MTC cohort initially comprises 102 MTC 
patients with MEN2A. Linking their pedigrees to the 
MEN2A patients from the RET cohort provided 22 addi-
tional MEN2A patients satisfying criterion 4). Accord-
ingly, 124 MEN2A patients were uncovered from the 
MTC cohort, but only 34 were new patients. Of these, 22, 
11, and one fulfilled criteria 4), 2) and 1), respectively. 
The latter patient was a C634R carrier genetic tested sub-
sequent to the end date of the RET cohort and unrelated 
to the other MEN2A families (Table 1). This resulted in 
241 MEN2A patients from 20 families.
4. The nationwide collaboration of all Danish MEN2 centers 
provided 136 MEN2A patients, all related to families 
already known. Eight of these patients had not been 
identified in the previous steps. Four met criterion 1) and 
four met criterion 2). This yielded 249 MEN2A families 
from 20 families. In relation to these, we detected 289 
first-degree relatives, who had not been RET tested.
5. A cross-check between the first-degree relatives and 
relevant cohorts supplied only one MEN2A patient. This 
patient had not been identified in prior steps and fulfilled 
criterion 2). Consequently, 250 MEN2A patients from 20 
families had been detected.
6. A cross-check of relevant cohort against one another 
discovered no additional MEN2A patients.
7. The systematic literature search found 240 citations. 
Removal of eleven duplicates and two triplets yielded 225 
unique citations, of which 65 had Danish affiliations. Full 
text was retrieved for all 65 citations. Nineteen reported 
of MEN2A patients in Denmark.7,8,21–24,26–38 From these 
citations, we found 34 MEN2A patients. All had been 
uncovered through previously used sources.
In total, we ascertained 250 MEN2A patients from 20 
families. Criteria 1), 2), 3), and 4) were met by 158, 22, 48, 
and 22 patients, respectively.
All 250 patients were included for prevalence calcula-
tions, while the 190 patients born in Denmark between 
January 1, 1901, and December 31, 2014, were included for 
incidence calculations.
The investigation was approved by the Danish Health 
Authority (3-3013-395/3) and the Danish Data Protection 
Agency (18/17801). The Regional Committees on Health 
Research Ethics for Southern Denmark found that further 
review was not liable to notification (S-20132000-69).
Incidence
Incidence was calculated as the number of MEN2A patients 
born in Denmark in each decade divided by the number of live 
births in Denmark for the respective decade. To estimate the 
incidence of MEN2A, we used the period from 1971 to 2000, 
equivalent to that previously used to estimate the incidence 
of MEN2B in Denmark.3
Danish population data were retrieved from Statistics 
Denmark (www.statbank.dk).
Prevalence
Point prevalence for each year from 1901 to 2015 was cal-
culated as the number MEN2A patients alive at January 1 
divided by the number of inhabitants alive at the same date.
Statistical analysis
Time trends in incidence were evaluated by Poisson regres-
sion. P-values<0.05 were considered significant. All analyses 
were done using Stata® 15.0 (StataCorp LP, College Station, 
TX, USA).
Results
Among the 250 MEN2A patients included, 118 were female 
and 132 were male yielding a female–male ratio of 0.89. The 
RET mutation carriers were distributed as follows: 169 (68%) 
C611Y carriers, 16 (6%) C618Y carriers, 16 (6%) C611W 
carriers, 12 (5%) C620R carriers, 10 (4%) D631Y carriers, 9 
(4%) C634R carriers, 6 (2%) V804M carriers, 5 (2%) L790F 
carriers, 4 (2%) C618F carriers, 2 (1%) C634Y carrier, and 
1 (0%) C634Y+Y791F carrier.
Most index cases had inherited their RET mutation. Only 
in one case was the mutation (C620R) molecularly proven 
to be de novo, as both parents were tested negative for the 
mutation. Also, haplotype analysis failed to relate the index 
case to the two other Danish C620R families.8
Incidence
Table 2 depicts the incidence of MEN2A by decade and muta-
tion. No significant change in incidence from 1901 to 2014 
was seen for the specific mutations or for the overall group 
of MEN2A (P>0.05) (Table 2). The incidence from 1971 to 
2000 was 28 (95% CI: 21–37) per million live births per year.
Prevalence
Figure 2 shows the point prevalence of MEN2A per million 
according to January 1 in each year from 1901 to 2015. The 
point prevalence at January 1, 2015, was 24 per million 
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(95% CI: 20–28) (5,659,715 inhabitants in Denmark and 
136 MEN2A patients alive).
Discussion
In this nationwide study of 250 unique MEN2A patients 
born or resident in Denmark before December 31, 2014, we 
report an incidence of 28 per million live births per year and 
a point prevalence of 24 per million.
Limitations
To estimate the true number of MEN2A patients in a country, 
the entire population should ideally undergo RET testing at 
birth. To the best of our knowledge, this is not the case any-
where in the world. Instead, we conducted a comprehensive 
Table 2 Incidence of MEN2A in Denmark according to decade and mutation
10-year birth cohorts (190 carriers) P for 
trend1901–1910
(741,557
live births)
1911–1920
(725,875
live births)
1921–1930
(712,148
live births)
1931–1940
(662,390
live births)
1941–1950
(853,113
live births)
1951–1960
(761,648
live births)
1961–1970
(792,197
live births)
1971–1980
(672,095
live births)
1981–1990
(557,279
live births)
1991–2000
(673,654
live births)
2001–2010
(643,356
live births)
2011–2014
(229,657
live births)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
C611W 1 (1.3) 1 (1.4) 0 0 2 (2.3) 1 (1.3) 0 1 (1.5) 2 (3.6) 0 1 (1.6) 0 0.85
C611Y 4 (5.8) 10 (14) 13 (18) 11 (17) 11 (13) 19 (25) 15 (19) 11 (16) 16 (29) 13 (19) 9 (14) 4 (17) 0.06
C618F 0 0 0 1 (1.5) 1 (1.2) 0 2 (2.5) 0 0 0 0 0 0.87
C618Y 2 (2.7) 0 0 3 (4.5) 0 2 (2.6) 1 (1.3) 0 0 4 (5.9) 0 0 0.95
C620R 1 (1.3) 0 1 (1.4) 0 3 (3.5) 1 (1.3) 2 (2.5) 0 3 (5.4) 1 (1.5) 0 0 0.74
D613Y 0 0 1 (1.4) 0 0 0 0 0 0 0 0 0 0.40
C634R 0 0 0 1 (1.5) 1 (1.2) 4 (5.3) 2 (2.5) 0 0 1 (1.5) 0 0 0.77
C634Y 0 0 0 0 0 0 0 0 0 0 0 1 (4.4)
L790F 0 0 0 0 0 0 0 0 0 2 (3.0) 0 0 0.15
V804M 1 (1.3) 1 (1.4) 0 0 1 (1.2) 0 1 (1.3) 0 0 0 0 0 0.18
All MEN2A 9 (12) 12 (17) 15 (21) 16 (24) 19 (22) 27 (35) 23 (29) 12 (18) 21 (38) 21 (31) 10 (16) 5 (22) 0.07
Abbreviation: MEN2A, multiple endocrine neoplasia 2A.
Figure 2  Point prevalence of multiple endocrine neoplasia 2A in Denmark at 
January 1 according to years.
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search in the Danish RET cohort, linkage of MEN2A pedi-
grees, the Danish MTC cohort, a nationwide collaboration 
of MEN2 centers, cross-checking of other relevant cohorts, 
and a systematic literature search. This virtually depleted 
all possibilities to identify MEN2A patients in Denmark 
and enabled us to study the incidence and prevalence for the 
entire 20th century.
The registries used have different coverage in terms of cal-
endar time, potentially having an impact on the incidence and 
prevalence estimates. Except for the Danish Cancer Registry, 
none of the utilized registries existed during the first half of 
the century. Similarly, fewer MEN2A patients born in the first 
part than in the second part of the century survived until the 
introduction of RET testing in Denmark (September 1994). 
Thus, the incidence and prevalence may be underestimated in 
the first half of the century, although pedigree linkage identified 
several MEN2A patients born in this period.
In our cohort, the MEN2A diagnosis was verified by RET 
testing in 63% (158/250). In 34% (86/250), genetic in vivo 
testing was never possible, as patients had died or emigrated 
before RET testing became available in Denmark or before the 
first MEN2A diagnosis was made in their respective families. 
However, if only considering patients included for calcula-
tions of incidence 1901–2014, incidence 1971–2014, and 
point prevalence at January 1, 2015, the figures for MEN2A 
diagnosis verified by RET testing increased to 80%, 100%, 
and 97%, respectively.
Despite our meticulous search and high proportion of 
RET-tested MEN2A patients for the reported incidence and 
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Table 2 Incidence of MEN2A in Denmark according to decade and mutation
10-year birth cohorts (190 carriers) P for 
trend1901–1910
(741,557
live births)
1911–1920
(725,875
live births)
1921–1930
(712,148
live births)
1931–1940
(662,390
live births)
1941–1950
(853,113
live births)
1951–1960
(761,648
live births)
1961–1970
(792,197
live births)
1971–1980
(672,095
live births)
1981–1990
(557,279
live births)
1991–2000
(673,654
live births)
2001–2010
(643,356
live births)
2011–2014
(229,657
live births)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
Patients, n
(per 1 million 
and year)
C611W 1 (1.3) 1 (1.4) 0 0 2 (2.3) 1 (1.3) 0 1 (1.5) 2 (3.6) 0 1 (1.6) 0 0.85
C611Y 4 (5.8) 10 (14) 13 (18) 11 (17) 11 (13) 19 (25) 15 (19) 11 (16) 16 (29) 13 (19) 9 (14) 4 (17) 0.06
C618F 0 0 0 1 (1.5) 1 (1.2) 0 2 (2.5) 0 0 0 0 0 0.87
C618Y 2 (2.7) 0 0 3 (4.5) 0 2 (2.6) 1 (1.3) 0 0 4 (5.9) 0 0 0.95
C620R 1 (1.3) 0 1 (1.4) 0 3 (3.5) 1 (1.3) 2 (2.5) 0 3 (5.4) 1 (1.5) 0 0 0.74
D613Y 0 0 1 (1.4) 0 0 0 0 0 0 0 0 0 0.40
C634R 0 0 0 1 (1.5) 1 (1.2) 4 (5.3) 2 (2.5) 0 0 1 (1.5) 0 0 0.77
C634Y 0 0 0 0 0 0 0 0 0 0 0 1 (4.4)
L790F 0 0 0 0 0 0 0 0 0 2 (3.0) 0 0 0.15
V804M 1 (1.3) 1 (1.4) 0 0 1 (1.2) 0 1 (1.3) 0 0 0 0 0 0.18
All MEN2A 9 (12) 12 (17) 15 (21) 16 (24) 19 (22) 27 (35) 23 (29) 12 (18) 21 (38) 21 (31) 10 (16) 5 (22) 0.07
Abbreviation: MEN2A, multiple endocrine neoplasia 2A.
prevalence calculations, we cannot rule out that some patients 
may not have been captured. In fact, as of this writing, a 
Danish L790F family is undergoing genetic workup after the 
presentation of MTC (T1bN0M0) in a 70-year-old index case. 
This exemplifies that carriers of RET mutations classified in 
the American Thyroid Association’s moderate category1 and 
carriers unaware of their MEN2A family history may not 
have been captured yet. Therefore, our figures of incidence 
and prevalence should be regarded as minimum estimates.
Incidence
In the present study, we found an incidence of 28.4 per mil-
lion live births per year from 1971 to 2000.
A German study reported the incidence of MEN2A from 
1951 to 2000, with the highest incidence found from 1991 to 
2000.2 If excluding carriers of the benign Y791F variant,15,39 
the incidence in this period can be calculated as 8.1 (95% 
CI: 6.2–10) per million live births per year. During the same 
period, our incidence was 31 (95% CI: 19–48) per million 
live births per year. Another study found the incidence of 
MEN2A in Norway from 1965 to 2015 to be 1 per 66,438 
live births per year corresponding to 15 (95% CI: 11–20) per 
million live births per year.5 In the same period, the incidence 
in Denmark was 25 (95% CI: 20–31) per million live births 
per year corresponding to 1 per 40,102 live births per year.
The Danish incidence was higher compared with both the 
German and the Norwegian incidence. The difference in the 
German incidence could likely be explained by ascertainment 
as the population in our study included all of Denmark, while 
the German study estimated a coverage of at least half of all 
RET carriers born in the period of 1991–2000.2 Even though 
the Norwegian study is nationwide,5 one might speculate that 
the difference in the Danish incidence is also due to ascertain-
ment, as inclusion in the Norwegian study was based solely 
on a systematic search within all four Norwegian departments 
of medical genetics, while our inclusion was based on a sys-
tematic search in the Danish RET cohort, linkage of MEN2A 
pedigrees, the Danish MTC cohort, a nationwide collaboration 
of MEN2 centers, cross-checking of other relevant cohorts, 
and a systematic literature search. However, if we include 
only patients identified from the RET cohort, being the best 
comparison with the Norwegian method, the Danish MEN2A 
incidence in the given period at 24 (95% CI: 19–30) per live 
birth per million still appears higher than the Norwegian. A 
more likely explanation to the difference in incidence may 
be the C611Y founder effect in Denmark, accounting for an 
unusually high incidence of C611Y carriers.8 This is sup-
ported by the fact that 74% (60/81) of MEN2A patients born 
in Denmark between January 1, 1965, and January 1, 2015, 
were carriers of the C611Y mutation. Unfortunately, the 
Norwegian study did not specify the carrier status of MEN2A 
patients included in the incidence calculations, but because 
only five carriers of codon 611 mutations were included in the 
entire study, the percentage of C611Y carriers in incidence 
calculation could maximally be 11% (5/44). This suggests 
that the large proportion of C611Y carriers in the Danish 
MEN2A population is the main reason for the disparity seen 
in incidence between the two Scandinavian countries.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 0
2-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1486
Mathiesen et al
Prevalence
Based on 5,659,715 inhabitants and 136 MEN2A patients 
living in Denmark at January 1, 2015, we found a point 
prevalence of 24 per million. Similarly, 5,165,000 inhabitants 
and 65 MEN2A patients were living in Norway at March 1, 
2015, yielding a point prevalence of 13 per million.5 Thus, 
the point prevalence in Denmark seems somewhat higher 
compared with that of Norway.
Again, if only including patients (n=131) identified from 
the RET cohort for the Danish prevalence calculations, the 
prevalence still appears higher than that in Norway. Also, for 
prevalence calculations, the proportion of C611Y carriers in 
Denmark (99/136) was substantially higher than the corre-
sponding proportion in Norway (5/65) under the assumption 
that all codon 611 mutation carriers in Norway were in fact 
C611Y carriers and alive at prevalence day. Thus, the most 
likely explanation for the difference in MEN2A prevalence 
recorded between the two countries seems to be the Danish 
C611Y founder effect.8 Similarly, other populations with sup-
posed or proven RET founder mutations may also experience 
a rather high MEN2A prevalence.40–42
In our study, the prevalence was steadily increasing until 
the beginning of the 1960s, most likely caused by buildup 
of the cohort with continuing recruitment exceeding the rate 
of exit, a phenomenon known from other rare conditions 
as well.43 The prevalence will be stable when recruitment 
equals exit (death or emigration). We do not have any obvi-
ous explanation why the prevalence is decreasing after 2000.
Conclusion
The incidence and prevalence of MEN2A in Denmark seems 
to be higher than those reported in other countries. This is 
likely explained by the Danish C611Y founder effect. Also, 
our data indicate no significant change in MEN2A incidence 
during the last century.
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